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Broadly speaking, medicine seeks to provide (i) accurate diagnosis, effective treatment, and informative prognosis, as 
well as (ii) various preventive interventions of which immunization is the most notable.  Healthcare providers can also, in
special circumstances, prescribe preventive measures, which can be given even after exposure to certain infectious
diseases, but before infection, or clinical manifestations develop. Depending on the infection in question, these measures 
may consist of antibiotics, vaccines, or immune globulins (singly or in combination) and are referred to as “Post-exposure
prophylaxis” or simply “PEP.”  A familiar example of PEP is provision of a suitable antibiotic to household contacts of 
persons with invasive meningococcal infection.  This is one of the classic examples of PEP, as data that form the basis for 
the practice come from studies conducted over 30 years ago (The Meningococcal Disease Surveillance Group, 1976).  
Another classic, and nowadays even more common, example of PEP is the provision of antibiotics to household contacts
of patients with pertussis.  
In the past, provision of PEP has largely been the province of public health efforts provided in the community.  However,
in February 2011 the South Carolina Board of Medical Examiners (SCBME) updated its policy which now not only explicitly
approves, but indeed recommends that practicing physicians provide PEP in situations where PEP is recommended by 
recognized professional and public health organizations (SCBME, 2011)1. (See box, page 5.) This is usually done in 
collaboration with DHEC in a public-private partnership. 
(Continued on page 4)
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Central-line associated blood stream infections (CLABSIs) are serious infections 
that occur when bacteria enter the bloodstream through a vascular catheter.  
Approximately 80,000 CLABSIs occur in the U.S. each year, with an annual cost 
of $296 million to $2.3 billion over the anticipated cost of care.  These infections
have been shown to prolong hospitalization for 5-20 days, with an attributable 
cost of $34,000-56,000 per patient.  Since October 1, 2008, Medicare has not 
allowed payment for costs associated with vascular catheter-associated infections
that were not present on admission. 
In South Carolina, currently 81 facilities report CLABSIs and certain surgical site 
infections (SSIs) to the Department of Health and Environmental Control (DHEC) 
through the National Healthcare Safety Network (NHSN).  Data are tracked by 
NHSN using a Standardized Infection Ratio (SIR), which compares the actual 
(Continued on page 11)
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Web Resources to Bookmark 
Compiled from DHEC Website (www.scdhec.gov) 
How do I manage an animal bite where there is a 
concern about rabies: 
Find it: SCDHEC.gov home page >> In the News >> 
Physician Guide to Rabies Post-Exposure Prophylaxis
Click it: DHEC Guide to Managing Animal Exposures 
and Rabies Postexposure Prophylaxis
What diseases are reportable, and when? 
Find it: SCDHEC.gov home page >> Diseases and 
Conditions >> Resources and Programs >> Click 
Reportable Conditions. 
Click it: SC List of Reportable Conditions and 
Laboratory List of Reportable Conditions (PDF). The 
Reportables.htm page can be read on a phone, 
tablet, etc.
Where can I find a quick reference with 
information for health professionals on diseases 
and DHEC resources? 
Healthcare Professionals Quick Reference: 
Find it: SCDHEC.gov home page >> Diseases and 
Conditions. Click any of the Conditions that interest 
you, OR 
Find it: SCDHEC.gov home page >> Diseases and 
Conditions >> Resources and Programs >> 
Healthcare Professionals’ Quick Reference
Click it: Healthcare Professionals’ Quick Reference. 
Acute Disease Epidemiology A-Z Quick Index
(covers all of the reportable conditions) 
Find it: SCDHEC.gov home page >> Diseases and 
Conditions >> Resources and Programs >> A-Z 
Disease Resources. 
Click it: A-Z Disease Resources
How bad is the flu this year? 
Find it: SCDHEC.gov home page >> Data, Reports & 
Statistics >> Flu (Influenza)
Click it: South Carolina Influenza Activity and 
Surveillance [Current] Season
Where are the latest Health Alerts? 
Find it: SCDHEC.gov home page >> In the News >> 
Health Alert Network >> Latest Public Health 
Notifications
Click it: Public Health Notifications (posted by year) 
What shots are required for school or childcare 
this year? 
Find it: SCDHEC.gov home page >> Healthy Living & 
Prevention >> Topics >> Immunizations >> 
Immunization Division >> From the Box on the left: 
Childhood, Adolescent & Adult Immunizations >> 
Immunization Requirements for School and Day Care, 
2011-2012. 
Click it: Immunization Requirements for School and 
Day Care 2011-2012 (pdf) 
If you are a health 

professional 

interested in receiving 

health notifications 

from the South 

Carolina Health 

Alert Network, 

please contact Shana 

Dorsey, HAN 

Coordinator at 803-
898-0431 or email 

DADE-
OC@dhec.sc.gov. 
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Epi Clips 
Compiled by staff in the SC DHEC Division of Acute 
Disease Epidemiology
Reports received by SC DHEC for animal bites, 

where rabies PEP was recommended by a 

healthcare provider: 

January 1 through November 30, 2011 

# of Bites for which PEP was Mammal Species recommended (%) 
Bat  16 (24.6) 

Cat 4 (6.2) 

Dog  26 (40.0) 

Fox 3 (4.6) 

Raccoon  13 (20.0) 

Other Wild  3 (4.6) 

Animal testing data courtesy of 
Sue C. Ferguson, REHS/RS
Director, Division of General Sanitation
SC DHEC Bureau of Environmental Health 
  
 
 
 
 
 
 
  
 
 
 
 
 
  
Epi Notes Fall 2011 Page 4 
Post-Exposure Prophylaxis in the Office Setting
(Continued from page 1)
EPT 

In the last few years, a similar intervention has been
introduced in relation to certain sexually transmitted 
diseases. This is referred to “Expedited Partner 
Therapy” (EPT), which is the practice of treating the sex 
partners of patients diagnosed with chlamydia, gonorrhea 
or trichomoniasis by providing prescriptions or 
medications to the patient to take to his/her partner 
without the health care provider first examining the 
partner. The CDC devotes an entire web page 
(www.cdc.gov/std/ept) to EPT, which contains useful
links to numerous informative statements and 
endorsements of EPT from the American Medical 
Association, the American College of Obstetricians and 
Gynecologists and other medical organizations, as well as 
legal points of view from the American Bar Association.  
Recognizing the importance of both PEP and EPT, the 
SCBME has now clarified that “PEP” or “Epi-treatment” of 
Sexually Transmitted Diseases can and should be 
provided “even in the absence of a previously established 
patient-physician relationship.”  The full text of the 
Medical Board’s policy is shown in the box on page 5. 
The rest of this article provides further information and 
context concerning the importance of such modes of 
therapy which need to be provided both (i) to prevent 
disease in persons so treated, as well as (ii) to help 
interrupt the “chain of transmission” of the infectious
“Expedited Partner Therapy” is the practice of 
treating the sex partners of patients diagnosed 
with chlamydia, gonorrhea, or trichomoniasis by 
providing prescriptions or medications to the 
patient to take to his/her partner, without the 
health care provider first examining the partner. 
agent in question and thus further protect family 
members, sex partners, and indeed the public at large. 
Conceptual Framework for Basis Post-exposure
Prophylaxis Recommendations 
Figure 1 presents a schematic view of the “stages” in the 
natural history of an infectious process, i.e., stages
through which an infection may typically progress in the 
absence of any medical intervention.  Preventive 
measures (so called primary, secondary, and tertiary
prevention) thus serve to prevent progression from one 
stage to the next (Friis & Sellers, 2004).  This model 
clarifies that PEP can best be conceptualized as a 
secondary prevention strategy, which prevents 
progression from asymptomatic infection to clinically 
manifest infection. 
(Continued on page 5)
Figure 1: 4 stages in the natural history of infection. Primary, secondary, and tertiary prevention are shown “blocking” 
the arrows, thus preventing progression to the next stage of illness. 
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Post-Exposure Prophylaxis in the Office Setting
(Continued from page 4)
POST EXPOSURE PROPHYLAXIS POLICY 
The SC Board of Medical Examiners, at its February 2011 meeting, voted to amend its policy regarding PEP as 
follows: 
Post-Exposure Prophylaxis (PEP) or Epi-treatment of Sexually Transmitted Diseases (STDs), including Expedited 
Partner Therapy (EPT), is often recommended by numerous medical professional and public health organizations 
(notably the Centers for Disease Control [CDC], the American Public Health Association/ World Health Organization’s 
Control of Communicable Diseases Manual, the American Academy of Pediatrics Red Book, or the South Carolina 
Department of Health and Environmental Control [DHEC]) to protect specific persons from acquiring contagious/ 
communicable diseases from close contact with infected persons. The SC Board of Medical Examiners approves and 
recommends the prescribing of PEP or Epi-treatment (including EPT) of STDs in accordance with the most current 
established guidelines as published by these organizations, even in the absence of a previously-established patient-
physician relationship (SCBME, 2011)
As shown in Table 1, the measures constituting primary, secondary, and tertiary prevention vary, depending on the 
infectious disease in question. 
Table 1: Examples of Primary, Secondary and Tertiary Prevention for Selected Infectious Diseases 
Disease
Primary 
Type of Prevention
Secondary Tertiary
Tuberculosis
Wearing a mask when in room 
with a person with 
infectious TB.
BCG vaccine is used as primary 
prevention in many 
countries, despite limited 
efficacy.
INH serves as preventive 
therapy: it is used against 
latent TB infection (LTBI) in 
order to prevent 
subsequent progression of 
LTBI to TB disease.
Treatment of TB disease to
avoid destruction of lung 
tissue, dissemination of 
infection, or death.
Hepatitis B
Routine hepatitis B 
immunization (e.g. per 
standard infant vaccination
schedule or for HCWs).
Precautions when using 
"sharps" in clinical settings.  
Condoms to avoid sexual 
transmission.
PEP with HB Immune Globulin 
and/or vaccine following 
various exposures (e.g., 
needle sticks; sexual 
exposure; birth to a HBsAg
positive mother.) 
Anti-viral therapy to try to
eradicate infection.
Liver transplantation to avoid 
Hepatitis B virus-associated
liver failure and death. 
Antibiotic PEP for household 
(and selected other) 
contacts to cases in order Treatment of invasive 
Meningococcal Immunization with to prevent recently meningococcal infection to 
Disease meningococcal vaccine. acquired naso-pharyngeal prevent severe sequellae or 
colonization/ infection from death. 
progressing to invasive 
meningococcal infection.
(Continued on page 7)
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Post-Exposure Prophylaxis in the Office Setting
Table 2: Selected Infectious Diseases for which PEP and/or EPT are often required.
Most common and/or ofType of 	 Examples of Indications Typical PEP Disease	 greatest likely importance Refs ** pathogen	 for PEP regimens*
for office-based physician.
Zoonotic Rabies Person bitten by an animal HRIG Day Zero + ~400 rabies PEP/yr in SC.  PEP 	 (CDC, 
2008a,viral 	 proven to be, or suspected to most often initiated in ED withVaccine on days 0, 3, 7 2010a)infection be rabid (and animal not 	 follow-up vaccine doses& 14 
available for testing and/or administered in office or by 
observation	 pharmacist 
Viral 

infections 

transmitted 

Influenza Household contacts*** Oseltamavir YES (CDC, 
2011) 
(CDC,Hepatitis A Household contacts. 1 dose of Hepatitis A Now uncommon in SCfrom person 2007b)Patrons of restaurant with an vaccine or IGto person
infected worker. 
(CDC,Hepatitis B 	 Household contacts. HCWs Hepatitis B vaccine often HCW exposures more likely 
2001,suffering needles sticks. (not always) in handled in Employee Health 
2005c, Discreet sexual exposure. conjunction with HBIG. Setting.  Newborn exposures 2006,
handled in hospital setting. 2008b) 
Bacterial 

Infections 

Tuberculosis 	 Household contacts. INH or Rifampin Most TB contacts managed 
Selected work or other (along with nearly all SC TB 
contacts. cases) in DHEC clinics. 
Pertussis Household contacts. 
Selected day-care, school or 
other contacts. 
Azithromycin YES (CDC, 
2005b) 
Invasive 
Meningococcal Selected day-care, school or or Ceftriaxone 
Disease
Household contacts.
other contacts. 
 Ciprofloxacin, Rifampin YES (CDC, 
2005a) 
(CDC, 
2000, 
2003) 
Sexually 
Transmitted 
Infections 
**** 
Gonorrhea Sexual partner(s) Ceftriaxone or Cefixime 
(+ treatment for 
possible or likely 
Chlamydia co-infection) 
YES
Chlamydia Sexual partner(s) Azithromycin or 
Doxycycline (+treatment 
for possible or likely 
gonococcal co-infection)
YES
Trichomonas Sexual partner(s) Metronidazole YES
(CDC, 
2010b) 
(*) Full details on PEP regimens (e.g., selection and doses of antibiotics) may be found in standard references, as well as in the links in the 

references section.  In many instances, PEP may be provided through a single dose of immune globulin, vaccine or antibiotic.   

(**) Most references in this table are to recommendations that appeared in CDC’s Morbidity and Mortality Weekly Report, accessible from
 
http://www.cdc.gov/mmwr. Recommendations are also available via standard texts, including the Red Book (American Academy of 

Pediatrics, 2009) or Control of Communicable Diseases Manual (American Public Health Association, 2008) . 

(***) The table lists “Household contacts” to cases of influenza as “examples” of persons for whom PEP with oseltamivir may be prescribed.  

However, the most detailed guidelines on the subject (Centers for Disease Control and Prevention, 2011) further nuance the recommendation 

by indicating that PEP should be considered especially for those who are at higher risk of influenza complications but have not been 

vaccinated against the influenza strains circulating at the time of exposure. Persons at such risk include those who (i) are ≤2 or ≥65 years of 

age, (ii) have certain chronic medical conditions, (iii) are morbidly obese, and (iv) women who are pregnant or post-partum (within 2 weeks 

of delivery). 

(****) Syphilis contacts must receive injected penicillin G benzathine as PEP.  However, these persons are also typically examined, as well as
 
tested, at the time of treatment. 
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Post-Exposure Prophylaxis in the Office Setting
(Continued from page 5)
Post-Exposure Prophylaxis in Every Day Practice 
Over time, physicians may deal with many dozens of different viral, bacterial, or other pathogens.  From a practical point 
of view, however, the number of infections for which physicians in practice may provide PEP or EPT is generally limited.  
Table 2 (previous page) lists 10 conditions for which PEP or EPT may be indicated.  Highlighted items are conditions that 
are commonly encountered and/or conditions of greatest importance in primary care practice setting. 
Examples of Public-Private Partnerships for Provision of PEP and EPT
Though standard references from the CDC, the AAP, APHA, and others recommend PEP and/or EPT in certain situations, 
they do not address the question of who should actually be responsible for writing the prescriptions. Fortunately, for 
providers in South Carolina, much of this ambiguity has now been resolved thanks to the 2011 Board of Medical 
Examiners policy (see Box , page 5) which now allows, and indeed recommends that PEP and EPT prescriptions 
can be written by practicing physicians even in the absence of an established patient-provider relationship. 
By way of examples, Table 3 presents three situations in which PEP or EPT is indicated for contacts to ill/infected persons.  
It suggests a practical division of responsibility in which the patient’s primary care physician assumes responsibility of 
providing PEP for the immediate family, while DHEC would assume responsibility for a broader public health investigation 
and provision of PEP in a wider circle of contacts (e.g., in school, work or other setting as may be appropriate.) 
Table 3:  Examples of Public-Private Collaboration for Provision of PEP or EPT 
Case Situation
Shared Responsibility for PEP/EPT 
Patient's Primary Care 
Physician (§) DHEC (public health)
8 year-old child diagnosed with 
pertussis by his primary care 
physician by means of PCR and 
culture for Bordetella pertusss.
Child's mother has heard from 
parents of classmates that other 
children in school are also suspected 
as having pertussis.
Provides PEP with 
azithromycin 
prescriptions for the 
household members 
(e.g. for two parents, 
two sibling and a live-in 
aunt)
In collaboration with principle and school 
nurse, investigates the child's 
elementary school. 
Identifies other cases. 
Arranges for information letters to parents. 
Recommends PEP for subset of  school 
children (and selected other contacts) 
21 year-old year college student Prescribes PEP prescriptions 
hospitalized with meningococcal for household members 
meningitis. Lives in college dorm (student's immediate 
Monday-Thursday and at home family).
Friday-Sunday. Just back from trip 
with college volleyball team.
Coordinates investigation with the college 
and makes recommendations as to 
which dorm members such as  
roommates, suite-mates, others (e.g.
girl friend, fellow team members) 
should receive PEP. 
Coordinates PEP as indicated with college 
health service and/or families of the 
other students in question.
(§) In some settings, PEP may be prescribed by an Emergency Department (ED) physician rather than by the patient's primary care provider: 
e.g. toxic patient with meningeal signs found to have Gram negative diplococci in ED spinal tap and admitted with provisional diagnosis of 
meningococcal meningitis.  ED physicians may also provide PEP prescriptions on the spot for family members who have brought the patient to
the ED as well as for other family members at home.
(Continued on page 8)
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Post-Exposure Prophylaxis in the Office Setting
(Continued from page 7)
Table 3:  Examples of Public-Private Collaboration to Provision of PEP or EPT  (continued)
Case Situation
Shared Responsibility for PEP/EPT 
Patient's Primary Care 
Physician (§) DHEC (public health)
26 year-old woman found to have 
chlamydial cervicitis by her OB-GYN 
physician.
Treats patient for chlamydial 
infection and for possible 
gonococcal co-infection. 
Provides EPT for her partner 
by writing prescriptions 
for the same drugs 
which she can carry to 
him.
In simplest scenario (e.g. patient with 
uncomplicated infection and only one 
partner) DHEC typically not involved. 
However, in more complex scenarios, (e.g. 
patient also identified via laboratory 
surveillance to have co-infection with 
syphilis or HIV) DHEC may assist with 
partner notification, interviews, testing 
and treatment as indicated
Summary 
Control of certain infectious diseases requires treatment of not only cases, but also PEP for household and other contacts 
at risk of becoming cases themselves. In South Carolina, the State Board of Medical Examiners approves and 
recommends that physicians2 provide PEP for family members (or EPT for sex partners) at risk.  DHEC may 
then focus its increasingly limited resources on assuring that PEP will be provided to other community 
contacts at risk as indicated by a public health investigation.  Such public-private collaboration is in the best 
interests of patients’ families and of the community at large.  This modus operandus is emerging as the standard of care
in efforts to control selected infectious diseases of public health importance. 
Endnotes 
1. 	 Organizations promulgating authoritative guidance for postexposure prophylaxis include the Centers for Disease Control and 
Prevention, the American Academy of Pediatrics, the American Public Health Association, the Infectious Disease Society of 
America, and the American Thoracic Society.
2. 	 The SC Board of Nursing has not issued a specific advisory opinion on the prescribing of PEP or EPT by advanced practice 
registered nurses in the absence of a provider-patient relationship.   
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Summary of Conditions reported to SC DHEC January 1 through November 30, 2011 
Compiled by Claire Youngblood, MA, Data Manager 

Division of Acute Disease Epidemiology 

Condition Confirmed Probable‡ Suspect‡ 
Animal Bite, PEP Recommended 65 0 0 
Aseptic meningitis 178 1 1 
Campylobacteriosis 374 14 0 
Cholera 1 0 0 
Creutzfeldt-Jakob Disease 0 1 0 
Cryptosporidiosis 63 62 1 
Dengue Fever 1 2 2 
Ehrlichiosis, chaffeensis 2 1 0 
Ehrlichiosis, Human granulocytic 0 0 1 
Ehrlichiosis/Anaplasmosis, undetermined 0 1 0 
Encephalitis, LaCrosse 0 1 0 
Giardiasis 108 3 2 
Group A Streptococcus, invasive 103 0 0 
Group B Streptococcus, invasive (<90 days of age) 46 0 0 
Haemophilus influenzae, invasive 71 0 8 
Hansen disease (Leprosy) 0 0 0 
Hemolytic uremic syndrome, postdiarrheal 3 0 0 
Hepatitis A, acute 11 0 4 
Hepatitis B, acute 35 0 28 
Hepatitis B virus infection, Chronic 97 376 12 
Hepatitis B virus infection, Perinatal 0 0 0 
Hepatitis C, acute 1 0 0 
Hepatitis C Virus Infection, past or present 3,235 13 143 
Hepatitis Delta co- or super-infection, acute 1 0 0 
Hepatitis E, acute 2 0 1 
Influenza, human isolates 496 0 0 
Legionellosis 21 0 2 
Listeriosis 7 0 0 
Lyme disease 24 11 182 
Malaria 5 0 1 
Mumps 2 0 1 
Neisseria meningitidis, invasive (Mening. disease) 9 0 0 
Novel Influenza A Virus Infection 7 0 0 
Pertussis 80 56 13 
Q fever (all: acute, chronic, not specified) 1 2 1 
Rubella 0 1 0 
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Summary of Conditions reported to SC DHEC January 1 through November 30, 2011 
Condition Confirmed Probable‡ Suspect‡ 
S. aureus, vancomycin intermediate susc (VISA) 3 0 0 
Salmonellosis 1,486 10 0 
Scombroid Fish Poisoning 1 0 0 
Shiga toxin-producing Escherichia coli (STEC) 17 0 14 
Shigellosis 57 50 0 
Spotted Fever Rickettsiosis 12 23 95 
Strep pneumoniae, invasive 406 0 2 
Streptococcal disease, invasive, IPD 1 0 0 
Streptococcal toxic-shock syndrome 2 0 0 
Tetanus 0 1 0 
Toxic-shock syndrome, staphylococcal 0 3 0 
Tuberculosis 95 0 0 
Typhoid fever (Salmonella typhi) 1 0 0 
Vancomycin-resistant enterococcus 1 0 0 
Varicella (Chickenpox) (reportable only in outbreaks) 13 0 0 
Vibrio parahaemolyticus 7 0 0 
Vibrio spp., non-toxigenic, other or unspecified 2 0 0 
Vibrio vulnificus infection 2 0 0 
West Nile Fever 0 1 0 
Yersiniosis 5 0 0 
‡ Not all conditions on this list have an “official” probable or confirmed status defined.  Case status indicated on these pages is based 
upon what is reported in the Carolina’s Health Electronic Surveillance System. 
Data are preliminary, and include only those reports for which a final cases status of confirmed, probable, or suspect has been
assigned. Conditions with zero cases may have no reports, or may be the subject of on-going investigations.  Most recent complete full 
-year data are available from the SC DHEC Annual Report on Reportable Conditions: http://www.scdhec.gov/health/disease/docs/ 
Annual Report on Reportable Conditions.pdf. Questions may be directed to the Surveillance Section of the SC DHEC Bureau of 
Disease Control’s Division of Acute Disease Epidemiology. 
Update on CLABSI Reporting 
(Continued from page 1)
number of infections with baseline experience (assumed 
predicted numbers) for the facility.  This yields a ratio of 
actual to predicted infections.  An SIR greater than 1.0 
indicates that more hospital acquired infections (HAIs) 
were observed than predicted; an SIR less than 1.0 
means fewer HAIs were observed than predicted.  
In March 2011, the CDC released data showing 
that, of 17 states with a mandate for reporting 
CLABSIs to NHSN, South Carolina was the only 
state to demonstrate a significant decrease in 
CLABSI SIRs.  South Carolina’s CLABSI rate dropped 
30% July to December 2009 when compared to January 
to June 2009, in continuously reporting facilities.  (http:// 
www.cdc.gov/VitalSigns/HAI/) 
Furthermore, South Carolina is one of only a few states 
validating the data entered by healthcare facilities.  
Employees in the Healthcare Associated Infections
Section of DHEC visit each facility and perform chart 
reviews to confirm the accuracy of data entered.  By 
performing these validations, South Carolinians can have 
confidence that the data are meaningful and correct.
Read more about HAIs, including the SC DHEC HIDA
Annual Report for 2010:  http://www.scdhec.gov/health/ 
disease/hai/
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
 
  
  
   
 
 
  
Epi Notes is published by the South Carolina 
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Bureau of Disease Control 

Division of Acute Disease Epidemiology 

DISEASE REPORTING
For immediately reportable conditions, call your 
local county health department or, for after
hours, call 1-888-847-0902.  Routine reports 
may be phoned in to your local health
department or mailed on a completed DHEC 
DISEASE REPORTING CARD (DHEC 1129.)  
Local county health department numbers are
listed on the Official List of Reportable
Conditions.   
For a copy of the current Official List of 
Reportable Conditions, call 803-898-0861 or 
visit www.scdhec.gov/health/disease.index.htm. 
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THE EPI NOTES IS AVAILABLE ONLINE AT 
www.scdhec.gov/health/disease/index.htm. 
Epi Notes, SC DHEC’s quarterly epidemiology publication, will be published in an 
internet & email-only format, starting with the 2nd 2011 issue.
Continue to receive our updates: 
Access the Epi Notes online from the Bureau of Disease Control’s webpage:  
• www.scdhec.gov/health/disease/
Subscribe to the Epi Notes for email delivery: 
• Send an email to DADE-OC@DHEC.SC.GOV with Epi Notes in the subject line,
or 
• Contact the Bureau of Disease Control (Phone: 803.898.0861,  
 Fax: 803.898.0897)
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